Aviceda Ophthalmics, Inc. announced it raised $49.5 Million in an initial filing from an offering of $79.7 Million

Company

Location

About

Aviceda Therapeutics is a disruptive clinical-stage biotech company focused on the next generation of immuno-modulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly using a propriety HALOS platform Technology. Aviceda is developing glyco-immuno therapeutics targeting devastating ocular and systemic degenerative, fibrotic, and immuno-inflammatory diseases.